title: A case of infliximab-induced psoriasis.
abstract: Anti-tumor necrosis factor (anti-TNF-alpha) are a group of new drugs able to inhibit the action of this cytokine. Although systemic side effects have been well described, cutaneous adverse reactions have not yet been clearly elucidated. The authors report a case of a 29-year-old man affected by Crohn disease and ankylosing spondylitis who developed psoriatic lesions after IV infusion of infliximab 5 mg/Kg. The patient underwent cyclosporine treatment after interruption of biological therapy, and had complete resolution of cutaneous lesions. The reason for this phenomenon is not clear, Obviously more studies are necessary to define more clearly this paradoxical reaction. In addition, dermatologists must be informed about this potential cutaneous adverse event.
authors.affiliation: Department of Cutaneous and Venereal Diseases and Plastic Surgery, Policlinico Umberto I, University of Rome La Sapienza, Rome, Italy. antoniorichetta@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Richetta
authors.forename: C
authors.initials: C
authors.lastname: Mattozzi
authors.forename: V
authors.initials: V
authors.lastname: Carlomagno
authors.forename: E
authors.initials: E
authors.lastname: Maiani
authors.forename: V
authors.initials: V
authors.lastname: Carboni
authors.forename: S
authors.initials: S
authors.lastname: Giancristoforo
authors.forename: S
authors.initials: S
authors.lastname: D'Epiro
authors.forename: F
authors.initials: F
authors.lastname: Bruni
authors.forename: S
authors.initials: S
authors.lastname: Calvieri
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D007710:Klebsiella Infections / Q000150:complications; D041121:Klebsiella oxytoca / Q000302:isolation & purification; D008297:Male; D010612:Pharyngitis / Q000150:complications / Q000382:microbiology; D011565:Psoriasis / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology / Q000503:physiopathology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000150:complications; D013290:Streptococcal Infections / Q000150:complications; D013292:Streptococcus agalactiae / Q000302:isolation & purification; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine; D000069285:Infliximab